Bio-Rad Labs Inc. A Stock
Bio-Rad Labs Inc. A Stock
Bio-Rad Labs Inc. A dominated the market today, gaining €11.20 (4.180%).
Currently there is a rather positive sentiment for Bio-Rad Labs Inc. A with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 322 € shows a slightly positive potential of 15.74% compared to the current price of 278.2 € for Bio-Rad Labs Inc. A.
For the coming years our community has positive and negative things to say abot the Bio-Rad Labs Inc. A stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Revenue growth" there were negative voices in the community.
Pros and Cons of Bio-Rad Labs Inc. A in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Rad Labs Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bio-Rad Labs Inc. A | 4.180% | 5.779% | 6.102% | 27.439% | 7.871% | -26.943% | -52.034% |
| Haemonetics Corp. | 2.840% | 2.174% | 3.676% | - | 2.920% | - | - |
| CONMED Corp. | 0.000% | -2.094% | 19.872% | -10.952% | 6.857% | -66.000% | -66.903% |
| Penumbra Inc | -0.360% | 0.647% | 0.791% | 42.270% | 5.180% | 0.791% | 29.124% |
Comments
Bio-Rad Laboratories (BIO) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $320.00 price target on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories (NYSE:BIO) had its price target raised by analysts at Citigroup Inc. from $350.00 to $375.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank Of Canada from $387.00 to $409.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat